TABLE 3.
Characteristics of selected differentially expressed serum biomarkersc
| m/z (kDa) | Mean intensity (cutoff) | No. of positive samples |
% Sensitivity | % Specificity vs VHC, CHC, and OPD groups | % Specificity vs VHC and CHC groups | % Specificity vs OPD group | |||
|---|---|---|---|---|---|---|---|---|---|
| CD (n = 131) | VHC (n = 104) | CHC (n = 60) | OPD (n = 140) | ||||||
| 3.7 | 1.65 | 126 | 2 | 2 | 4 | 96.9 | 97.4 | 97.6 | 97.1 |
| 4.4 | 2.87 | 125 | 3 | 0 | 4 | 95.4 | 97.7 | 97.6 | 97.1 |
| 5.4a | 1.29 | 9 | 101 | 60 | 135 | 93.2 | 97.4 | 98.2 | 96.4 |
| 6.3b | 1.75 | 13 | 1 | 0 | 2 | 9.9 | 99.0 | 99.4 | 98.6 |
| 6.6 | 2.23 | 126 | 1 | 1 | 5 | 96.1 | 97.7 | 98.8 | 96.4 |
| 7.5b | 2.96 | 11 | 1 | 1 | 1 | 8.4 | 99.0 | 98.8 | 99.3 |
| 7.8 | 3.67 | 128 | 6 | 2 | 38 | 97.7 | 84.9 | 95.1 | 72.8 |
| 8.1 | 1.21 | 129 | 3 | 2 | 10 | 98.4 | 95.0 | 96.9 | 92.8 |
| 9.3 | 4.1 | 129 | 4 | 2 | 6 | 98.5 | 96.0 | 96.3 | 95.7 |
| 10.1 | 1.74 | 129 | 4 | 2 | 6 | 98.5 | 96.0 | 96.3 | 95.7 |
| 12.7 | 1.97 | 128 | 2 | 0 | 2 | 97.7 | 98.7 | 98.8 | 98.6 |
| 13.6 | 2.05 | 111 | 10 | 2 | 16 | 84.7 | 90.8 | 92.7 | 88.6 |
| 15.2b | 1.26 | 14 | 1 | 1 | 1 | 10.7 | 99.0 | 98.8 | 99.3 |
| 16.3 | 1.06 | 126 | 2 | 2 | 6 | 96.2 | 96.7 | 97.6 | 95.7 |
| 24.7 | 1.83 | 124 | 10 | 1 | 3 | 94.6 | 95.4 | 93.3 | 97.8 |
| 28.1a | 2.89 | 7 | 104 | 60 | 136 | 94.6 | 98.7 | 98.8 | 97.1 |
| 28.9 | 1.98 | 125 | 2 | 0 | 2 | 95.4 | 98.7 | 98.8 | 98.6 |
| 75.4 | 0.89 | 125 | 4 | 2 | 6 | 95.4 | 96.0 | 96.3 | 95.7 |
a
Downregulated protein in CD-positive subjects.
b
Upregulated protein in Guatemalan CD-positive children with abnormal EKG readings.
c
Sera were obtained from CD-positive subjects (CD), including all Guatemalan children (with normal and abnormal EKGs) and Venezuelan adults identified in blood donor clinics, from Venezuelan healthy control blood donors (VHC), from Canadian healthy controls (CHC), and from control patients infected with other parasites (OPD).